Related Experiment Video
Updated: Jun 15, 2026
08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Alzheimer's disease is incurable but preventable.
1Center for Alzheimer's Research, Banner Sun Health Research Institute, Sun City, AZ 85351, USA. jcdelatorre@comcast.net
Journal of Alzheimer'S Disease : JAD
|February 26, 2010
Summary
Preventing Alzheimer's disease (AD) is more feasible than curing it. A novel screening method, CAUSE+ABI, detects cardiovascular risks early in asymptomatic individuals for timely intervention.
Area of Science:
- Neurology
- Cardiology
- Preventive Medicine
Background:
- Alzheimer's disease (AD) poses a significant and growing public health challenge.
- Current treatments are limited, especially after cognitive decline, making prevention a more viable strategy.
- Existing screening methods for AD risk lack specificity in identifying causes and interventions.
Purpose of the Study:
- To propose and evaluate a cost-effective, non-invasive mass screening strategy for early detection of Alzheimer's disease risk factors.
- To identify modifiable cardio-cerebrovascular risk factors amenable to early intervention in asymptomatic individuals.
- To advocate for evidence-based medicine in managing AD risk.
Main Methods:
- Utilizing a combination of carotid artery ultrasound, echocardiography, and ankle-brachial index (CAUSE+ABI) for mass screening.
- Applying these tests to asymptomatic individuals to detect underlying cardio-cerebrovascular abnormalities.
- Integrating findings with evidence-based medicine for clinical decision-making.
Main Results:
- CAUSE+ABI is proposed as a simple, cost-effective, and accurate method for detecting AD risk factors.
- The screening identifies individuals with cardio-cerebrovascular abnormalities before cognitive symptoms manifest.
- Early detection facilitates timely and potentially more successful interventions.
Conclusions:
- Preventive strategies targeting modifiable risk factors are crucial for managing Alzheimer's disease.
- CAUSE+ABI offers a promising approach for early, cost-effective screening and intervention in asymptomatic populations.
- Early detection and intervention are key to improving outcomes and reducing the burden of Alzheimer's disease.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.